January 29, 2026- Abbott announced new five-year data demonstrating that its neuromodulation therapies, including its proprietary BurstDR™ spinal cord stimulation (SCS) waveform and dorsal root ganglion stimulation technology, can significantly reduce pain-related healthcare visits for people living with chronic pain. The data, shared at the North American Neuromodulation Society 2026 Annual Meeting in Las Vegas, highlight Abbott’s continued commitment to advancing long-term, patient-centered solutions that address the clinical needs and everyday challenges of chronic pain.
A retrospective analysis presented at NANS showed that Abbott’s SCS therapy reduced the number of pain-related healthcare visits in both the short- and long-term, with patients reducing their pain-related care by an average of 75% after five years of SCS use.